Galaxy Medical Receives $18 Million from ATP to Advance Development of Its Novel Pulsed Electric Field Ablation Therapy for Cardiac Arrhythmias
Galaxy Medical Receives $18 Million from ATP to Advance Development of Its Novel Pulsed Electric Field Ablation Therapy for Cardiac Arrhythmias --Galaxy's proprietary CENTAURI™ system on track for EU registration and US pivotal trial start later this year; shows best-in-class potential News provided by Share this article Share this article SAN CARLOS, Calif., March 16, 2021 /PRNewswire/ -- ATP, a leader in life science venture capital, announced today $18M in Series A financing for its portfolio company Galaxy Medical, Inc. The funds are being used to advance the development of Galaxy's fla...